HOPKINTON, Mass., Aug. 8 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. today announced that the Company will host a conference call on Wednesday, August 15th, 2007 at 10:00am EDT to review the second quarter of 2007 and discuss other matters related to the Company.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )
To access the conference call, please dial (800) 310-6649 for domestic and (719) 457-2693 international. The code for this conference call is 6487100. Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of the call will be posted on the Investor Relations section of the website, http://www.alseres.com , within 48 hours following the conference call and will be available through Wednesday, August 29th, 2007.
About Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. Cethrin(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. The Company has reported positive interim results in a Phase I/IIa clinical trial, of ALTROPANE(R), a molecular imaging agent, is in Phase III clinical trials for the diagnosis of Parkinson's Disease (PD). The Company's research and pre-clinical CNS programs include Inosine for the treatment of spinal cord injury and stroke, a DAT blocker for the treatment of Parkinson's disease, and a second generation technetium-based molecular imaging agent for PD and ADHD. Alseres' current research collaborations include Harvard Medical School and Children's Hospital Boston.
Safe Harbor
The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres Pharmaceuticals' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of ALTROPANE and Cethrin, the prospects of the Company's CNS therapeutics program, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres Pharmaceuticals from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres Pharmaceuticals is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.
Contact: Sharon Correia -- 508-497-2360 ext. 224
Alseres Pharmaceuticals, Inc. scorreia@alseres.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comAlseres Pharmaceuticals, Inc.CONTACT: Sharon Correia of Alseres Pharmaceuticals, Inc., +1-508-497-2360ext. 224, scorreia@alseres.com
Web site: http://www.alseres.com/
